Prescriptions must be issued by a primary care physician or licensed medical doctor practicing within the USA, and must be written in English
Gall bladder/bile duct disease Acute pancreatitis and other pancreatic disorders have been reported, though the relationship to treatment is unclear Injection-site reactions Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Primary mechanism(s) of action Selectively binds and activates both GIP and GLP-1 receptors Example Tirzepatide (Mounjaro) Dosage Initial: 2.5 mg subcutaneous injection once weekly, titrated up to 5 mg weekly after 4 weeks If additional glycemic control is needed, dosage can be increased in 2.5 mg increments after at least 4 weeks on the current dosage
Pentadecapeptide BPC 157 enhances the GH receptor expression in tendon fibroblasts
Lower back in compression, upper legs in tension
Retatrutide is designed for long-term use, not short-term weight loss followed by discontinuation
After proposals begin being accepted on August 1, 2024, direct contact with topic authors is no longer allowed
